Elite Pharmaceuticals Inc. Reports 48% Revenue Increase to $84 Million for Fiscal Year Ending March 31, 2025, Driven by Product Launches and Elite Label Sales

Reuters
07/01
Elite Pharmaceuticals Inc. Reports 48% Revenue Increase to $84 Million for Fiscal Year Ending March 31, 2025, Driven by Product Launches and Elite Label Sales

Elite Pharmaceuticals Inc. has reported significant financial results for the fiscal year ended March 31, 2025. The company's total revenues saw an impressive increase of $27.4 million, or 48%, reaching $84.0 million compared to $56.6 million in the previous year. This substantial growth was primarily driven by four product launches during the current fiscal year, alongside boosted sales from the Elite Label product line. Manufacturing fees revenue experienced a notable rise of $27.9 million, or 51%, compared to the previous year, largely due to the same factors contributing to the overall revenue growth. In contrast, licensing fees revenue saw a decline of $0.4 million, or 18%, as the company shifted away from licensing products to third parties. On the expenses front, research and development costs increased by $1.1 million, or 16%, totaling $8.0 million, while general and administrative expenses rose by $1.9 million, or 26%, amounting to $9.0 million. The company did not provide outlook or guidance for future periods in the report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017134), on June 30, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10